Check out what we have in store for you in the March Newsletter
Dear Hepatitis C Advocaters,
The March issue is ready for your viewing. Before we get to this month’s newsletter I want to bring to your attention a new site within our website group:
The Hepatitis C Advocate Pipeline & Conference Coverage site: on this site you will find information about drugs in development to supplement our Drug Pipeline, and we will have coverage from major conferences (EASL and AASLD). We will also post abstracts about hepatitis with brief editorial comments. The new site will include a search engine option as well as a drop down menu “categories” that have been indexed by a list of major topics. We will notify our website audience of new postings via our Facebook and Twitter accounts.
The new site will join our other sites within our website group including:
Hepatitis C Medication site that lists all the approved direct-acting medications to treat chronic hepatitis C searchable by genotype and drug name, and
Clinical Trial Reference Guide that lists clinical trials studies for hepatitis C patients by countries and we have updated the clinical trials in America by state
The March 2017 HCV Advocate newsletter has the following news articles:
- HealthWise – Why We Need to Treat Everyone Who Has Hepatitis C by Lucinda K. Porter, RN – Lucinda explores how to eliminate hepatitis C in this thought-provoking article.
- Under The Umbrella—The Pros and Cons of Learning about Hepatitis C on the Internet by Matthew Zielske—Matthew writes about the pros and cons of educating ourselves and others about hepatitis C on the internet.
- SnapShots by Alan Franciscus.In this month’s column, I write about three studies—the new liver chemistry guidelines issued, potential liver injury from herbal and dietary supplements, and an analysis about the treatment using Zepatier in people with compensated cirrhosis.
- The Drug Pipeline has been pretty quiet this month with the exception of the news that AbbVie’s two drug combination of glecaprevir plus pibrentasvir to treat all genotypes (pan-genotypic) had been granted an FDA priority review – meaning that the drug approval process will be speeded up.
- What’s Up! – In this month notice we have updated the following fact sheets:
Alan and the staff of the HCV Advocate
Share This Page